Faruqi & Faruqi Investigates Inovio Investor Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INO?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims from investors who purchased securities between October 10, 2023, and December 26, 2025, indicating a focus on the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance and urgency of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers to enhance accessibility and confidence in legal support for investors.
- Potential Impact Assessment: This investigation could negatively affect Inovio's stock price and market confidence, prompting investors to monitor legal developments closely to adjust their investment strategies accordingly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.550
Low
3.00
Averages
7.33
High
13.00
Current: 1.550
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovalis Real Estate Investment Trust Reports Q4 and Full Year 2025 Results
- Financial Overview: Inovalis Real Estate Investment Trust reported a Q4 AFFO of -$0.23 and full-year revenue of $6.72 million, with a provision for income tax payable related to a dispute with the French tax administration materially affecting both Q4 and full-year FFO, which stood at -($0.20) and -($0.19) per Unit, respectively, highlighting significant financial strain due to tax issues.
- Non-Recurring Item Impact: Excluding this non-recurring tax burden, the full-year 2025 FFO was $0.02 per Unit, reflecting the REIT's solid underlying occupancy and debt profile, although overall financial metrics remain weak.
- Capital Expenditure Investment: During 2025, the REIT invested $2,670 in capital expenditures, primarily for value-enhancing tenant improvements at the Neu-Isenburg property, indicating a continued focus on enhancing asset value.
- Annual AFFO Analysis: The annual AFFO for 2025 was -($0.26) per Unit, or -($0.05) per Unit excluding the tax reassessment provision, suggesting that cash flow remains under pressure until the tax dispute is resolved.
See More
Faruqi & Faruqi Investigates Inovio Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims from investors who purchased securities between October 10, 2023, and December 26, 2025, indicating a focus on the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance and urgency of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers to enhance accessibility and confidence in legal support for investors.
- Potential Impact Assessment: This investigation could negatively affect Inovio's stock price and market confidence, prompting investors to monitor legal developments closely to adjust their investment strategies accordingly.
See More
Reminder of Class Action for Inovio Pharmaceuticals Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply to be lead plaintiff by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, claiming deficiencies in the manufacturing of its CELLECTRA device, which hindered its ability to timely submit the INO-3107 Biologics License Application to the FDA, thereby impacting investor interests.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with a proven track record to ensure effective legal support in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Inovio Pharmaceuticals Class Action Reminder for Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, indicating significant investor losses due to the company's failure to timely submit its Biologics License Application.
- Stock Price Volatility: Following the release of its Q2 2024 financial results on August 9, 2024, Inovio's stock price fell by $0.27, or 3.1%, to close at $8.44 per share, reflecting market disappointment over the delayed submission of the BLA, which negatively impacted investor sentiment.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA under a standard review timeline instead of the anticipated accelerated review, causing the stock to drop by $0.56, or 24.45%, to $1.73 per share, further exacerbating investor losses and raising concerns about the company's regulatory strategy.
- False Statement Allegations: The class action alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose critical information regarding manufacturing deficiencies and regulatory prospects, which misled investors about the company's business and future outlook, potentially leading to severe legal repercussions.
See More
Inovio Faces Class Action Lawsuit from Investors
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Inovio in the Eastern District of Pennsylvania on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, to apply as lead plaintiffs.
- Allegations of Misrepresentation: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which impacted the likelihood of timely submission of the INO-3107 Biologics License Application (BLA), thereby misleading investors.
- Significant Stock Drop: Following the FDA's acceptance of the BLA for INO-3107, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on December 29, 2025, indicating market concerns regarding its regulatory prospects.
- Next Steps for Investors: Bragar Eagel & Squire encourages affected investors to reach out to discuss their legal rights, indicating the firm’s commitment to supporting investors in pursuing potential compensation for their losses.
See More
Reminder for Inovio Pharmaceuticals Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in class actions to ensure effective legal support, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Inovalis Real Estate Investment Trust Reports Q4 and Full Year 2025 Results
- Financial Overview: Inovalis Real Estate Investment Trust reported a Q4 AFFO of -$0.23 and full-year revenue of $6.72 million, with a provision for income tax payable related to a dispute with the French tax administration materially affecting both Q4 and full-year FFO, which stood at -($0.20) and -($0.19) per Unit, respectively, highlighting significant financial strain due to tax issues.
- Non-Recurring Item Impact: Excluding this non-recurring tax burden, the full-year 2025 FFO was $0.02 per Unit, reflecting the REIT's solid underlying occupancy and debt profile, although overall financial metrics remain weak.
- Capital Expenditure Investment: During 2025, the REIT invested $2,670 in capital expenditures, primarily for value-enhancing tenant improvements at the Neu-Isenburg property, indicating a continued focus on enhancing asset value.
- Annual AFFO Analysis: The annual AFFO for 2025 was -($0.26) per Unit, or -($0.05) per Unit excluding the tax reassessment provision, suggesting that cash flow remains under pressure until the tax dispute is resolved.
See More
Faruqi & Faruqi Investigates Inovio Investor Claims
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims from investors who purchased securities between October 10, 2023, and December 26, 2025, indicating a focus on the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance and urgency of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers to enhance accessibility and confidence in legal support for investors.
- Potential Impact Assessment: This investigation could negatively affect Inovio's stock price and market confidence, prompting investors to monitor legal developments closely to adjust their investment strategies accordingly.
See More
Reminder of Class Action for Inovio Pharmaceuticals Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply to be lead plaintiff by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, claiming deficiencies in the manufacturing of its CELLECTRA device, which hindered its ability to timely submit the INO-3107 Biologics License Application to the FDA, thereby impacting investor interests.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with a proven track record to ensure effective legal support in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Inovio Pharmaceuticals Class Action Reminder for Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, indicating significant investor losses due to the company's failure to timely submit its Biologics License Application.
- Stock Price Volatility: Following the release of its Q2 2024 financial results on August 9, 2024, Inovio's stock price fell by $0.27, or 3.1%, to close at $8.44 per share, reflecting market disappointment over the delayed submission of the BLA, which negatively impacted investor sentiment.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 BLA under a standard review timeline instead of the anticipated accelerated review, causing the stock to drop by $0.56, or 24.45%, to $1.73 per share, further exacerbating investor losses and raising concerns about the company's regulatory strategy.
- False Statement Allegations: The class action alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose critical information regarding manufacturing deficiencies and regulatory prospects, which misled investors about the company's business and future outlook, potentially leading to severe legal repercussions.
See More
Inovio Faces Class Action Lawsuit from Investors
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Inovio in the Eastern District of Pennsylvania on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, to apply as lead plaintiffs.
- Allegations of Misrepresentation: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which impacted the likelihood of timely submission of the INO-3107 Biologics License Application (BLA), thereby misleading investors.
- Significant Stock Drop: Following the FDA's acceptance of the BLA for INO-3107, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on December 29, 2025, indicating market concerns regarding its regulatory prospects.
- Next Steps for Investors: Bragar Eagel & Squire encourages affected investors to reach out to discuss their legal rights, indicating the firm’s commitment to supporting investors in pursuing potential compensation for their losses.
See More
Reminder for Inovio Pharmaceuticals Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in class actions to ensure effective legal support, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
